Group items tagged

Health authorities in India have launched an inquiry into an allegation that a local pharmaceutical regulator, in return for a bribe, helped switch samples of cough syrups that the World Health Organization (WHO) had linked to the deaths of children in Gambia before the samples were tested at an Indian laboratory, according to two government officials and documents reviewed by the Reuters news agency. In an April 29 letter to the Anti-Corruption Bureau (ACB) in Haryana state reviewed by the news agency, a lawyer named Yashpal accused the state's drug controller, Manmohan Taneja, of taking a bribe of 50 million rupees (£481,600 approx.) from local manufacturer Maiden Pharmaceuticals to help it switch the samples before an Indian government laboratory tested them. Maiden's factory is based in Haryana state. Reuters points out that it was unable to independently establish that any bribes were paid. Taneja did not respond to phone calls, messages or emails seeking comment. Maiden did not respond to requests for comment. The WHO said it had no knowledge of the allegation. Yashpal - who like some Indians uses only one name - did not say in the letter where he got the information, or provide evidence for his claim about the syrups made by Maiden. Reuters was unable to independently establish that any bribes were paid.

At the European Conference of Clinical Microbiology & Infectious Diseases (ECCMID) this year in Copenhagen, Denmark, data on a test that may detect HIV, hepatitis B, and hepatitis C from a single drop of blood are being presented. Hepatitis B or C claim the lives of over a million people each year. Every year, 1.5 million individuals contract HIV, and 650,000 people pass away from HIV-related causes. The World Health Organisation has made the elimination of all three viruses by 2030 one of its global health strategies but new tests are necessary if case numbers are to be reduced. The most common test for hepatitis B, hepatitis C and HIV involves taking a blood sample from a vein using a needle. While this method works extremely well, there is a potentially large reservoir of the three conditions in places where this method is not suitable. This could be prisons, drug rehabilitation centres and homeless shelters, where the taking of venous blood samples isn't always suitable or countries in which the shipping and refrigerated storage of blood samples can be challenging. Alternatives include dried blood spot tests, in which a single spot of blood is tested for nucleic acid from the three viruses.

The global COVID-19 Sample Collection Kits Market size is expected to account for USD 16.3 billion by 2027, according to a new report

Turning 21 is a significant milestone in a person's life, marking the transition into full-fledged adulthood. It's the age when responsibilities and possibilities both expand, opening the door to a world of new experiences and opportunities. Now that you've reached this exciting age, you're likely wondering what unique and exciting things you can do. Luckily for you, the list is extensive and varied. From exploring the world of wines to finding your own path in the professional world, let's dive into this thrilling journey of discovery together. Whether you're an adventurous spirit or a contemplative soul, there's something here for everyone. So buckle up, as we unfold the multitude of options that await you now that you're 21! Venturing into the World of Wines For many, turning 21 means being able to legally drink alcohol. If you're a wine enthusiast, then you'll be thrilled to know that there are several ways to explore the world of wines. You can take a trip to a local vineyard and sample different varieties or join a wine club for exclusive access to rare bottles and sommelier-led tastings. You can also visit a winery and go on guided tours and pairings to learn more about the production process. No matter which route you choose, you're sure to gain an appreciation for this age-old beverage and its many nuances. Many cities and towns offer wine festivals throughout the year, where you can sample different wines and mingle with fellow enthusiasts. If you're feeling particularly ambitious, you can even take a viticulture class to learn more about how grapes are cultivated and what qualities make up a good bottle of wine.

National Institute for Health and Care Excellence (NICE)'s diagnostic advisory committee has recommended the use of HM-JACKarc or OC-Sensor quantitative faecal immunochemical tests (FIT) in a draft guidance release for consultation on Wednesday (5 July). Under existing NICE guidance, FIT was already offered to some people presenting to primary care with symptoms suggestive of colorectal cancer, while others were immediately referred on the suspected cancer pathway. The new draft guidance will now see everyone receive a FIT. A sample is sent in the post to a laboratory where the amount of blood in the faeces is measured. The results are usually available within a week and people with 10 or more micrograms of haemoglobin in their faeces should then be referred for further investigation. Further assessment using colonoscopy, or CT colonography, is required to diagnose cancer. The tests cost between £4 and £5 per sample, and can correctly identify about 9 out of 10 people with colorectal cancer. The committee agreed it is important that GPs can refer people for colonoscopy without a positive FIT result if they think it is necessary and where symptoms persist. The institute believes that the recommendation of the tests should reduce the number of unnecessary colonoscopies, thus freeing up appointments for more non-urgent referrals. This should lead to 50% fewer referrals for urgent colonoscopies being made by GPs in primary care settings each year.

Chest pain is an alarming symptom that causes lot of anxiety and worry in people. From the Doctor's point of view, chest pain sets of a lot of alarms. Enter into the ER complaining of chest pain and the Doctor will rush you to the bed, strap an oxygen mask on you and order and ECG. While the ECG is being taken, he will draw a blood sample to test for Myocardial infarction. Though the above illustration may scare you, it's intention is not to scare but to educate on the seriousness with which chest pain is taken. However, in this article we aim to educate you on chest pain and how you can help when you or someone near you feels pain in the chest.

We offer the full range of blood test at home with results available as early as 48 hours. Mobile Phlebotomy offered for blood sample collection.

Axiva Sichem Pvt Ltd offers a wide range of PVDF Syringe Filters in sterile and non sterile category. This syringe filters intended for aqueous and organic solution samples.

Laboratory centrifuge are used for various applications by different end users. A centrifuge is a type of equipment with an inbuilt motor, and is used for spinning the liquid samples at a high speed. This is aimed at separating the various components comprising the liquid. This equipment is widely used in laboratories for various research purposes in the areas of chemistry, biology, and biochemistry.

Patients with advanced non-small cell lung cancer (NSCLC) may soon be offered a blood test to assess their treatment options, instead of having to provide a tumour sample for analysis.

American global healthcare company, Viatris, has launched a new rapid self-test for qualitative detection of antibodies developed after Covid-19 vaccinations. The firm is going to market the Covid-19 Neutralising IgG Serological self-test, manufactured by PRIMA Lab SA, in the UK market, which would check presence of neutralising antibodies after vaccination. The presence of antibodies indicates that a person has had an immune response to the Covid-19 vaccine, and not that protective immunity has been acquired. The self-test that can be performed easily at home with a small blood sample, delivers results in just 10 minutes and has a recommended retail price of sub £20. After two doses of the Covid-19 vaccine, the self-test has shown a seroconversion rate of 98.3 per cent for the Pfizer vaccine, 98.5 per cent for the AstraZeneca vaccine and 95.2 per cent for the Moderna vaccine. It recommended that the test be performed at least 14 days after completing the vaccination cycle.

Britain's biotech firm Avacta Group on Monday (January 10) announced halting sales of its Covid-19 rapid antigen lateral flow test AffiDX to replace antibodies in the device and increase its ability to diagnose the Omicron variant. The company stated that AffiDX is capable of detecting Omicron when the virus is present in high numbers in samples, but the sensitivity of the test reduces at lower viral loads. The performance of all rapid antigen tests came under scanner in wake of a large number of mutations in the Omicron variant. AffiDX contains both a proprietary Affimer reagent and a commercially available antibody. The Affimer reagent detects the Omicron variant with the same sensitivity as the Delta variant, and performance of the antibody is paired with the Affimer reagent in the test. This has been affected by the additional Omicron mutations, the firm said. Alastair Smith, chief executive of Avacta Group, said: "Our determination to only provide high quality, high performance diagnostic tests has led us to the correct decision to pause all marketing of the AffiDX® lateral flow antigen test. We have, of course, been unable to market the product in the UK since October 2021, as the product continues to await approval under the new CTDA regulatory process.

Major Highlights of the Sugar Beet Seeds Market report study: A detailed look at the global Sugar Beet Seeds Industry The report analyzes the global Sugar Beet Seeds market and provides its stakeholders with significant actionable insights The report has considered all the major developments in the recent past, helping the users of the report with recent industry updates The report study is expected to help the key decision-makers in the industry to assist them in the decision-making process The study includes data on market intelligence, changing market dynamics, current and expected market trends, etc. The report comprises an in-depth analysis of macroeconomic and microeconomic factors affecting the global Sugar Beet Seeds market Market Ecosystem and adoption across market regions Major trends shaping the global Sugar Beet Seeds market Historical and forecast size of the Sugar Beet Seeds market in terms of Revenue (USD Million) Recent industry development and consumer preference trends Competitive Landscape and player positioning analysis for the global Sugar Beet Seeds market Key products and solution offerings by major players and business strategies adopted Recommendations for new market entrants and current players operating in the market space Analysis of niche and potential segments (type, application, and regions/countries) anticipated to observed promising growth Key challenges faced by operating players in the market space Analysis of major risks associated with the market operations Get FREE PDF Copy @ https://www.marketresearchstore.com/sample/sugar-beet-seeds-market-794502?utm_source=diigo.com-VPL&utm_medium=Varsha

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

NHS England is set to roll out a new test this week that will help doctors to spot a rare form of eye cancer in babies in the womb. The NHS test developed at Birmingham Women's and Children's NHS Foundation Trust, identifies the risk of developing retinoblastoma in babies that can be monitored and treated sooner - increasing the chance of saving their eyesight and potentially their lives. The new non-invasive test can detect changes in the genes in DNA and is likely to identify around 50 infants with retinoblastoma each year, in the latest example of the NHS harnessing the power of genomics to diagnose and treat patients faster and more effectively. Non-Invasive Prenatal Diagnosis (NIPD) also means parents can be informed early in pregnancy if their child is at risk. "The blood sample test is taken from the mother before birth and tested and analysed for mutations, which can determine with almost 100 per cent accuracy if the baby will develop retinoblastoma," the NHS said.

India will make tests mandatory for cough syrups before they are exported, a government notice showed on Tuesday, after Indian-made cough syrups were linked to the deaths of dozens of children in Gambia and Uzbekistan. Any cough syrup must have a certificate of analysis issued by a government laboratory before it is exported, effective June 1, the government said in a notice dated May 22 and shared by the health ministry on Tuesday. India's $41 billion pharmaceutical industry is one of the biggest in the world but its reputation was shaken after the World Health Organization (WHO) found toxins in cough syrups made by three Indian companies. Syrups made by two of these companies were linked to the deaths of 70 children in Gambia and 19 in Uzbekistan last year. "Cough syrup shall be permitted to be exported subject to the export sample being tested and production of certificate of analysis," said the notice issued by the trade ministry. The health ministry did not immediately respond to a query on whether testing would be required for cough syrups sold in the domestic market.

The Medicines and Healthcare products Regulatory (MHRA) and Genomics England to launch a brand-new genetic research resource, known as a 'biobank' on Thursday (June 01) to tackle the issue of Adverse Drug Reactions (ADRs). Biobank will help to better understand how a patient's genetic makeup can impact the safety of their medicines. "The Yellow Card biobank, which will contain genetic data and patient samples, will operate alongside the MHRA's Yellow Card reporting site for suspected side effects and adverse incidents involving medicines and medical devices," said MHRA. The biobank pilot will officially begin on 1 June 2023 with participant recruitment commencing later this year, on 1 September. The sequencing of participants' genetic material will begin in Spring 2024, with initial research findings from the pilot due to be published in 2025. Genomics England will be supporting the MHRA with sequencing and storage of genetic material through use of their well-established and secure infrastructure.